KCM
AKYA

Kennedy Capital Management’s Akoya BioSciences AKYA Stock Holding History

Kennedy Capital Management’s Portfolio AKYA Stock Details AKYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-297,764
Closed -$1.38M – 685
2023
Q3 		$1.38M Sell
297,764
-2,259
-0.8% -$13K 0.03% 532
2023
Q2 		$2.22M Buy
+300,023
New +$2M 0.05% 444

Other funds holding AKYA

BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
SW
SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kennedy Capital Management's AKYA Position: Q4 2023 in Review

Kennedy Capital Management sold out of Akoya BioSciences (AKYA) in Q4 2023, closing a stake of 297,764 shares — an estimated $1.38M sold.

Kennedy Capital Management first reported a position in AKYA in Q2 2023 and held it in 2 quarters. The position peaked at $2.22M in Q2 2023. 65 funds tracked by Wall St. Rank hold AKYA as of Q4 2023.

  • Kennedy Capital Management reported no remaining Akoya BioSciences position as of Q4 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 297,764 Akoya BioSciences shares in Q4 2023, an estimated $1.38M.
  • Kennedy Capital Management first reported a position in Akoya BioSciences in Q2 2023 and held it in 2 quarters.
  • Kennedy Capital Management's Akoya BioSciences position peaked at $2.22M in Q2 2023.
  • 65 funds tracked by Wall St. Rank held Akoya BioSciences as of Q4 2023.

Based on Kennedy Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.